Microphthalmia-associated transcription factor (MITF) (MITF)

Microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix leucine zipper transcription factor that functions as the master regulator of melanocyte development, survival, and pigmentation [1, 8, 16]. It orchestrates the melanogenesis pathway by transactivating key enzymes such as tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT) [4, 11, 17]. In oncology, MITF is recognized as a lineage-specific oncogene in melanoma, where its amplification or the E318K mutation contributes to tumor progression and resistance to MAPK-targeted therapies [2, 6, 13]. The protein operates via a rheostat model, where high levels promote differentiation, intermediate levels drive proliferation, and low levels are associated with senescence or an invasive, stem-like phenotype [3, 12, 20]. Therapeutic targeting of MITF involves direct inhibitors like ML329, PROTAC degraders such as WZS0347, or indirect modulation through the MC1R-cAMP-PKA and MAPK/ERK signaling pathways [5, 10, 18]. Challenges in targeting MITF include potential side effects such as skin depigmentation and impacts on other MITF-dependent lineages like osteoclasts and mast cells [15, 21, 23].

Other names

WS2AbHLHe32MICMM8COMMADMelanocyte-inducing transcription factorClass E basic helix-loop-helix protein 32

Inhibition of MITF gene transcription, promotion of ubiquitin-mediated proteasomal degradation, and modulation of upstream signaling pathways such as the MC1R-cAMP-PKA and MAPK/ERK axes [1, 5, 10, 18].